

## INDEX

- ADVERTISING**  
low tar cigarettes, 371-372
- AGE FACTORS**  
arterial disease prevalence, 183-184  
atherosclerosis and smoking relationship, 32  
atherosclerosis, aortic aneurysm, and smoking relationship, 194  
cardiovascular disease mortality trends, 331  
cerebrovascular disease risk, 5, 8  
cessation attempts, 10-11, 370, 373  
CHD mortality, 7, 113, 128, 339, 352, 354  
CHD relationship, 75-76, 91, 92, 101-102, 133-134  
daily cigarette consumption, 10, 367, 373  
intermittent claudication prevalence, 184  
prevalence of smoking, 10, 259, 365-366, 373  
stroke incidence, 165-166, 171  
stroke mortality trends, 341
- ALCOHOL CONSUMPTION**  
CHD mortality relationship, 111-112  
CHD relationship, 68, 91  
coronary calcification relationship, 32  
lipoprotein level relationship, 96  
stroke risk factor, 162  
sudden cardiac death relationship, 104-105
- ALLERGY**  
tobacco allergy and cardiovascular effects, 55-56, 188-189
- AMISH**  
mortality, 126-127
- AMPUTATION**  
healing failure and smoking, 192
- ANGINA PECTORIS**  
carbon monoxide exposure and exercise tolerance, 186, 223
- ANGINA PECTORIS—Contd.**  
carboxyhemoglobin level, 223  
CHD manifestation, 67, 70-71  
incidence in Belfast, 84  
incidence in smokers with CHD, 213  
risk in female smokers, 102  
smoking relationship, 70, 77, 86-87
- AORTA**  
aneurysm diagnosis, 192  
aneurysm prevalence in smokers and nonsmokers, 45  
atherosclerosis and nicotine exposure, 50  
atherosclerosis and smoking, 22, 34, 46-48, 56  
atherosclerosis as cause, 16  
atherosclerosis development, 5, 18  
epidemiologic data, 194-195  
mortality trends, 341  
tobacco smoke effects in rats, 53
- ARTERIOSCLEROSIS**  
(See also **ATHEROSCLEROSIS**)  
angina pectoris relationship, 70  
carbon disulfide exposure relationship, 226  
cardiovascular disease causation, 5  
definition, 15  
mortality trends, 341  
percent attributable to smoking, 65  
underlying process of stroke, 340
- ATHEROMA**  
definition, 15  
small arteries of myocardium, 34
- ATHEROSCLEROSIS**  
(See also **ARTERIOSCLEROSIS**)  
age and smoking relationship, 194  
aortic aneurysm relationship, 192  
atherogenesis, 19-21  
cadmium exposure relationship, 227  
carbon monoxide exposure relationship, 223  
cardiac arrest, 69  
cardiovascular disease causation, 5

## INDEX

### **ATHEROSCLEROSIS—Contd.**

- clinical significance, 16-17
- definition, 15-16
- dietary cholesterol effect, 190
- epidemiologic studies, 21-48
- incidence in smokers and nonsmokers, 67
- literature reviews, 17
- mortality and smoking, 229
- natural history, 17-19
- nicotine effects, 216
- pathophysiologic mechanisms of tobacco smoke, 48, 50-54
- plasma triglyceride correlation, 181
- risk factors, 205-206
- severity trends, 343-344
- smoking cessation effects, 5
- smoking effects, 5-6
- topographic distribution, 18

### **BLOOD FLOW**

- nicotine and tobacco smoke effects, 189
- nicotine effects, 215
- smoking relationship, 187-188

### **BLOOD PRESSURE**

- (See also **HYPERTENSION**)
- CHD risk factor, 97-98, 108, 130, 134
- coronary atherosclerosis relationship, 33
- intermittent claudication relationship, 184
- intervention trial effects, 315, 317
- intervention trial for single risk factor, 300
- nicotine effects, 3, 215
- race factors, 77
- smoking cessation relationship, 96-97
- smoking relationship, 55, 96-97, 187-188

### **BODY FAT**

- CHD risk factors, 132

### **BODY WEIGHT**

- (See also **OBESITY**)
- smokers versus nonsmokers, 55
- smoking effect in baboons, 190
- stroke incidence relationship, 163
- sudden cardiac death risk factor, 104

### **CADMIUM**

- physiological effects, 226-227
- tobacco smoke constituent, 226

### **Cancer See NEOPLASMS**

### **CARBON DISULFIDE**

- arteriosclerotic diseases, as risk factor, 226

### **CARBON MONOXIDE**

- atherogenic effects, 5, 51-52
- blood levels in smoking baboons, 190
- cardiovascular disease relationship, 220, 222-224
- cardiovascular effects, 230
- chemistry, 219-220
- exercise tolerance relationship, 186
- fibrinolysis relationship, 187
- myocardial infarction risk, 229
- platelet adhesiveness relationship, 189-190
- steelworkers' exposure and CHD mortality, 111
- toxicologic effects, 9
- validation of self-reported smoking cessation, 245, 261

### **CARBONYL SULFIDE**

- atherosclerotic effects, 225

### **Catecholamines See EPINEPHRINE; NOREPINEPHRINE**

### **CENTRAL NERVOUS SYSTEM**

- nicotine effects, 213

### **CEREBROVASCULAR DISEASE**

- (See also **STROKE**)

- atherosclerosis of cerebral vasculature, 48
  - cerebral thrombosis incidence, 344
  - cessation of smoking relationship, 168
  - incidence trends, 344
  - morbidity and mortality, 159-160
  - mortality trends, 329, 340
  - oral contraceptives relationship, 168-171
  - prevention, 170
  - risk factors, 160-162, 168-171
  - smoking as risk factor, 5, 8, 162-166
  - subarachnoid hemorrhage, 5, 8, 167
  - transient ischemic attacks, 166-167
- ### **CESSATION OF SMOKING**
- (See also **EX-SMOKERS; REDUCTION OF SMOKING; SMOKING INTERVENTION TRIALS**)
  - attempts to quit, 10-11, 369-370, 373
  - blood pressure correlation, 96-97

## INDEX

### **CESSATION OF SMOKING—Contd.**

- CHD epidemiology, 243–283, 300–321
- CHD mortality rates, 8–10, 122–126, 128, 293–321
- definition in intervention trials, 246–247
- following cardiovascular events, 213, 215
- intervention trial effects, 9, 252, 257–258, 261, 264–271, 275, 278–279, 282–283
- peripheral vascular disease treatment, 5, 8, 179, 190, 192, 194
- peripheral vascular effects, 187–188
- stroke mortality risk, 168
- stroke prevention, 170
- sudden cardiac death risk, 7, 105
- validation of self-reports, 244–246, 258, 261, 265, 279–280, 305, 312

### **CHEROOT SMOKERS**

- myocardial infarction risk, 88

### **CHEWING TOBACCO**

- intermittent claudication relationship, 186

### **CHOLESTEROL**

(See also **DIET**; **LIPIDS**; **LIPOPROTEINS**)

- aortic tissue levels following smoke exposure, 219
- atherogenesis relationship, 19–20, 50–54, 216–217
- atherosclerosis and diet in rabbits, 189–191
- carbon monoxide, diet, and atherosclerosis, 223
- cardiovascular disease risk and blood levels, 205
- CHD risk, 5, 7, 89, 91–93, 96–100, 127, 129–130, 136, 344
- coronary atherosclerosis and serum levels, 53
- hypercholesterolemia prevalence, 346
- intermittent claudication and serum levels, 184
- intervention trial effects, 312–313, 315, 317
- intervention trials for single risk factor, 300
- myocardial infarction and serum levels, 165
- peripheral vascular disease relationship, 180–182, 184

### **CHOLESTEROL—Contd.**

- smoking and blood levels, 188, 224
- smoking and serum levels, 6, 56, 182
- stroke risk predictor, 161
- sudden cardiac death and serum levels, 104

### **CHRONIC OBSTRUCTIVE PULMONARY DISEASE**

(See also **EMPHYSEMA**)

- mortality trends, 333, 338–340
- smoking correlation, 228

### **CIGAR SMOKERS**

- aortic lesions, 194
- CHD mortality, 8, 122
- CHD risk, 86, 128
- coronary event risk, 76–77
- former cigarette smokers, 252
- inhalation avoidance, 212
- myocardial infarction risk, 88
- peripheral vascular disease risk, 191
- stroke mortality, 163
- thiocyanate elevation, 244

### **COFFEE CONSUMPTION**

- blood lipid effects, 182
- CHD risk factor, 91, 97
- stroke risk factor, 162

### **CORONARY ARTERIES**

- atherosclerosis in, 18
- atherosclerotic lesions after nicotine exposure, 50
- carbon monoxide effect on lipid metabolism in, 52
- smoking and atherosclerosis in, 22–34, 56

### **CORONARY HEART DISEASE**

(See also **MYOCARDIAL INFARCTION**)

- age factors in smoking effect, 112–113, 116–117, 128
- atherosclerosis as underlying cause, 16
- cessation of smoking and epidemiology, 5–6, 10, 122–126, 128, 293–321
- clinical manifestations, 67–71
- death certificate ascertainment, 69–70
- incidence studies, 342–343
- intervention trial effects on incidence, 9
- low risk populations, 126–127
- low yield cigarettes, 120–122, 128

## INDEX

### **CORONARY HEART DISEASE—Contd. DIET—Contd.**

mortality trends, 329, 334, 336,  
338-340, 348-352  
pipe and cigar smokers, 122, 128  
prevalence trends, 3  
prospective cohort studies, 105-113  
risk assessment, 129-136  
risk factor reduction and mortality  
trends, 344, 346-348  
risk factors, 91-93, 96-97  
smoking relationship, 4-8, 65-67,  
113-119, 127-128  
synergism among risk factors, 97-  
100  
treatment improvements, 348

### **COTININE**

cigar smokers' serum, 212  
nicotine metabolite, 212-213  
serum levels and uptake of particu-  
lates, 228  
urine concentration in smoking ba-  
boons, 190  
validation of self-reported cessation,  
245

### **CROSS-CULTURAL STUDIES**

atherosclerosis topographic distribu-  
tion, 18  
CHD incidence and mortality, 79-  
91

### **Demographic Factors See AGE FACTORS; EDUCATIONAL AT- TAINMENT; RACE FACTORS; SEX FACTORS; SOCIOECO- NOMIC STATUS**

### **DIABETES MELLITUS**

atherogenesis relationship, 20  
cardiovascular disease risk factor,  
205  
CHD incidence relationship, 89  
CHD risk factor, 91-92  
mortality trends, 334  
peripheral vascular disease rela-  
tionship, 179, 183, 185, 191  
prevalence, 346  
stroke risk factor, 162, 165

### **DIET**

(See also **CHOLESTEROL; SATU-  
RATED FATS**)  
atherogenesis correlation, 19-20  
CHD mortality relationship, 112  
high cholesterol diet, nicotine, and  
arterial damage, 50

nutritional status and smoking role  
in atherosclerosis, 33  
treatment of peripheral vascular  
disease, 179

### **Dose-Response Relationship See SMOKING PATTERNS**

### **DRUG INTERACTIONS**

atenolol physiologic effects in  
smokers, 186  
diazepam reactivity in smokers,  
222  
methacholine effects on norepineph-  
rine, 216  
norepinephrine effects of dimethyl-  
phenylpiperazinium, 216  
oxytremorine effects on norepineph-  
rine, 216  
phenacetin reactivity in smokers,  
222  
propranolol physiologic effects in  
smokers, 186

### **EDUCATIONAL ATTAINMENT**

cessation attempt frequency rela-  
tionship, 369  
cigarette consumption relationship,  
367

### **ELECTROCARDIOGRAM**

abnormalities as stroke risk factor,  
162-163, 165  
CHD risk prediction, 134  
intervention effect, 282  
nitrogen dioxide exposure and car-  
diac function, 226

### **EMPHYSEMA**

(See also **CHRONIC OBSTRUCTIVE  
PULMONARY DISEASE**)

cadmium exposure as risk factor,  
226  
nitrogen oxides exposure as risk  
factor, 226  
smoking relationship, 228

### **ENZYMES**

carbon monoxide affinity, 222-223

### **EPINEPHRINE**

nicotine effects, 213, 215-216  
plasma levels and smoking, 186

### **ERYTHROCYTES**

(See also **HEMATOCRIT**)

counts in smokers, 55  
nicotine effects in rabbits, 190

## INDEX

### EX-SMOKERS

(See also **CESSATION OF SMOKING**)

- aortic lesions, 47, 194
- atherosclerosis mortality, 229
- CHD incidence, 82
- CHD mortality, 5-6, 8
- death risk after myocardial infarction or angina, 105
- differences from smokers, 297
- peripheral arterial disease in women, 185
- stroke mortality, 163, 168

### FAMILY

wives' participation in intervention trials, 257, 260

### FETUS

(See also **MATERNAL SMOKING**)

- maternal cadmium administration effects on fetal brain in rats, 227
- maternal smoking effects, 189

### FIBRINOGEN

smoking effects, 55, 187

### FIBRINOLYSIS

nicotine effects, 218  
smoking effects, 55, 187

### FILTER CIGARETTES

(See also **LOW YIELD CIGARETTES**)

- carbon monoxide yields, 220
- cardiovascular disease incidence, 228
- CHD mortality effects, 8
- CHD risk, 120
- hydrogen cyanide removal, 224-225
- nicotine delivery, 210
- nitrogen oxide reduction, 225

### GLUCOSE

- atherogenesis and blood levels, 218
- intermittent claudication and blood levels, 184
- intolerance and peripheral vascular disease, 182
- smoking and blood levels in baboons, 55, 190

### HEART RATE

- atherogenesis correlation, 218
- nicotine effects, 3, 215-216
- smoking effects, 187

### HEIGHT

- CHD risk factor, 107
- stroke risk factor, 163

### HEMATOCRIT

(See also **ERYTHROCYTES**)

- nicotine effects in rabbits, 190
- smoking effects, 55, 187

### HEMOGLOBIN

- carbon monoxide binding, 222
- nicotine effects in rabbits, 190
- smoking effects, 55, 186-187

### HEREDITY

- cadmium-induced hypertension, 227
- CHD risk factor, 91-92, 108
- coronary disease history and platelet activation, 55
- stroke risk factor, 166

### HORMONES

- estrogen and myocardial infarction, 103
- nicotine effects on antidiuretic hormone secretion, 213

### HYDROGEN CYANIDE

- coronary arteries and aorta effects, 52
- serum thiocyanate as metabolite, 244
- tobacco smoke constituent, 224

### HYPERTENSION

(See also **BLOOD PRESSURE**)

- atherogenesis relationship, 20
- cadmium level relationship, 226-227
- cardiovascular disease risk factor, 205
- CHD risk factor, 5, 7, 89, 91-93, 127, 344
- educational campaign effects, 348
- mortality trends, 329, 341
- peripheral vascular disease relationship, 179, 181
- prevalence trends, 346
- renal artery stenosis, hypertension, and smoking relationship, 185
- stroke risk factor, 161-163, 165-166, 170, 340
- sudden cardiac death risk factor, 104

### IMMUNE SYSTEM

- alterations in smokers, 55-56
- hypersensitivity and tar exposure, 228

### INFLUENZA

- mortality trends, 334

## INDEX

- INVOLUNTARY SMOKING**  
atherosclerotic cardiovascular disease etiology, 186  
cotinine in urine of nonsmokers, 212-213
- KIDNEYS**  
cadmium localization, 226  
nicotine metabolism, 212  
renal artery stenosis, hypertension, and smoking interrelationship, 185
- LEAD**  
atherosclerosis and lead in drinking water, 227
- LEGISLATION**  
smoking restrictions in Finland, 279-280, 316
- LEUKOCYTES**  
elevation in smokers, 55-56  
nicotine effects, 190
- LINOLENIC ACID**  
CHD incidence and consumption, 86
- LIPIDS**  
(See also **CHOLESTEROL**)  
atherogenesis relationship, 19-21, 52-54, 217-218  
carbon monoxide and blood levels, 223-224  
dietary cholesterol and serum level, 190  
nicotine administration and serum level, 190  
race factors and plasma levels, 77  
smoking and serum levels, 219  
smoking serum levels in baboons, 190
- LIPOPROTEINS**  
atherogenic role, 21  
cadmium exposure relationship in pigeons, 227  
CHD incidence, 92  
hyperlipoproteinemia and atherogenesis, 20  
hyperlipoproteinemia and peripheral vascular disease, 180-181  
oral contraceptives and smoking effects, 104  
race factors, 77  
smoking effects, 6, 53, 54, 56, 93, 96, 188, 219  
stroke relationship, 161-163
- LIVER**  
cadmium accumulation, 226  
cirrhosis mortality trends, 334  
lipoprotein metabolism impairment and peripheral vascular disease, 182  
nicotine metabolism, 212  
protein synthesis and carbon monoxide exposure, 222
- LOW YIELD CIGARETTES**  
(See also **FILTER CIGARETTES**)  
cardiovascular disease relationship, 229-230  
CHD mortality effects, 8, 120-122, 128  
smoking pattern effects, 9, 210, 218, 230, 272  
stroke mortality relationship, 164-165
- LUNG CANCER**  
(See also **NEOPLASMS**)  
deaths in smoking intervention trials, 306, 309  
excess deaths attributable to smoking, 65  
mortality trends, 333, 338-339
- LUNGS**  
nicotine metabolism, 212
- LYMPHOCYTES**  
smoking effects in baboons, 190
- LYSOSOMES**  
nicotine effects, 219
- MASS MEDIA**  
in smoking intervention trials, 263-264, 270, 272, 278-279, 281-283, 316
- MATERNAL SMOKING**  
(See also **FETUS**)  
fetal cardiovascular effects, 189  
umbilical artery changes, 219
- MENOPAUSE**  
CHD risk, 7, 101-104, 127
- MORMONS**  
CHD mortality, 126
- MORTALITY**  
calculations, 333, 356  
cardiovascular disease mortality trends, 329-344  
cardiovascular disease risk factor reduction effects, 344-348  
cessation of smoking effects, 8-9, 194, 293-321

## INDEX

- MORTALITY—Contd.**  
CHD mortality and smoking relationship, 4, 7, 65–66, 113–128, 348–353  
CHD mortality trends, 339–341  
coronary care improvement effects, 348  
prospective studies of CHD mortality, 105–113
- MYOCARDIAL INFARCTION**  
(See also **CORONARY HEART DISEASE**)  
carbon monoxide exposure correlation, 51  
carboxyhemoglobin level relationship, 223  
cardiac arrest etiology, 69  
case-fatality trends, 344  
CHD manifestation, 67  
clinical manifestations, 67–68  
discharge rate trends, 344  
free fatty acid elevation in smokers following myocardial infarction, 219  
hyperlipoproteinemia in survivors, 181  
incidence, 342–343  
mortality trends, 339–340  
nicotine and carbon monoxide delivery relationship, 229  
oral contraceptive use as risk factor, 7, 128  
smoking as risk factor, 72–75, 77–79, 84–89, 91, 101–102, 105, 108, 121, 165  
zinc deficiency correlation, 227
- MYOCARDIUM**  
atherosclerosis of small arteries, 34
- MYOGLOBIN**  
carbon monoxide binding, 222
- NEOPLASMS**  
(See also **LUNG CANCER**)  
cancer deaths in smoking intervention trial, 306, 310  
cancer mortality in Seventh Day Adventists, 126  
cerebral neoplasms and stroke, 166  
death rates and smoking patterns, 81  
respiratory tract cancer mortality and smoking, 81
- NICOTINE**  
atherosclerosis pathogenesis, 5, 48, 50–51  
blood flow effects, 189  
blood pressure and heart rate effects, 3  
cardiovascular effects, 213, 215–219, 230  
chemistry, 209–212  
fibrinolysis relationship, 187  
hematologic effects, 190  
metabolism, 212–213  
myocardial infarction risk, 229  
particulate uptake and serum levels, 228  
peripheral vascular effects, 187–188  
serum lipid effects, 190  
toxicologic effects, 9  
validation of self-reported smoking cessation, 245  
yields in U.S. cigarettes, 210
- NICOTINE CHEWING GUM**  
smoking intervention, 270
- NITROGEN OXIDES**  
coronary artery and aorta effects of nitric oxide, 52  
nitric oxide, carbon monoxide, and atherosclerotic changes, 225  
tobacco smoke constituents, 225–226
- NOREPINEPHRINE**  
nicotine effects, 213, 215–216  
smoking and plasma levels, 186
- OBESITY**  
(See also **BODY WEIGHT**)  
atherosclerosis and smoking interrelationships, 31, 46  
cardiovascular disease risk factor, 205  
CHD risk factor, 91, 92  
lipoprotein level relationship, 96  
stroke risk factor, 162
- OCCUPATIONS**  
farm laborers, 133–134  
grade of employment and CHD mortality, 110–111  
industrial workers, 275–278, 280–282, 303, 314–315  
nurses, 102  
physicians, 65, 110, 112, 123–124, 164, 297  
steelworkers, 111

## INDEX

- ORAL CONTRACEPTIVES**  
CHD risk factor with smoking, 101-104, 128  
myocardial infarction and smoking interrelationships, 7  
stroke risk factor with smoking, 166-171  
subarachnoid hemorrhage and smoking interrelationships, 5, 8
- PERIPHERAL VASCULAR DISEASE**  
animal studies, 189-190  
atherosclerosis as underlying cause, 16  
cessation of smoking effects, 190-192, 194  
clinical investigations, 186-189  
diagnosis, 179  
epidemiologic studies, 182-186  
reactivity of patients to tobacco glycoprotein, 56  
risk factors, 180-182, 194  
smoking effects, 8  
treatment, 179-180
- PERSONALITY**  
cardiovascular disease risk factor, 205  
CHD risk factor, 91-93
- PHYSICAL ACTIVITY**  
cardiovascular disease risk, 205  
CHD risk, 91-92, 132  
exercise tolerance and carbon monoxide exposure, 186  
stroke incidence, 162  
treatment of peripheral vascular disease, 179
- PIPE SMOKERS**  
aortic lesions, 47, 194  
CHD mortality effects, 8, 122  
CHD risk, 86, 128  
coronary event risk, 76-77  
former cigarette smokers, 252  
myocardial infarction risk, 88  
peripheral vascular disease risk, 191  
stroke mortality, 163  
thiocyanate elevation, 244
- PLATELETS**  
adhesiveness and carbon monoxide effects, 189-190  
atherogenesis role, 217-219  
nicotine effect in rabbits, 190  
smoking effects, 6, 55-56, 187
- PLATELETS—Contd.**  
smoking effects in baboons, 190  
thrombocytopenia as stroke risk factor, 166
- PNEUMONIA**  
mortality trends, 334
- PROSTAGLANDINS**  
nicotine effects and atherogenesis, 218-219
- RACE FACTORS**  
aortic aneurysms and atherosclerosis, 194  
atherosclerosis in aorta, 46  
atherosclerosis in coronary arteries, 22, 31  
atherosclerosis severity trends, 343-344  
cardiovascular disease mortality trends, 331  
cerebrovascular disease incidence, 170  
CHD incidence, 77-79, 132-134  
CHD mortality, 339  
hypertensive disease mortality trends, 341  
lipoprotein levels, 93  
prevalence of smoking, 364-365  
smoking patterns, 77  
stroke mortality, 159, 165, 341
- RECIDIVISM**  
rate following intervention trials, 261-263, 265
- REDUCTION OF SMOKING**  
criteria for successful intervention, 245-247  
intervention trial effects, 9, 256, 258, 262, 264, 275, 279-280, 309, 311-313, 315  
peripheral vascular disease patients, 191
- REFLEXES**  
nicotine effects, 213
- REORGANIZED CHURCH OF JESUS CHRIST OF LATTER DAY SAINTS**  
mortality rates, 126
- SATURATED FATS**  
(See also DIET)  
consumption trends, 348  
diet and atherogenesis, 19  
lipoprotein composition relationship, 53

## INDEX

### SEVENTH DAY ADVENTISTS

CHD and cancer mortality, 126

### SEX FACTORS

(See also **WOMEN**)

aortic aneurysm mortality, 194

brain infarction and myocardial infarction, 159

cessation attempts, 11, 373

CHD mortality, 110-113, 339

CHD mortality and smoking cessation trends, 348-352

CHD rates, 7

cigarette consumption trends, 10, 366-367, 373

lipoprotein levels, 93

peripheral vascular disease prevalence, 184-185

smoking patterns, 7

smoking prevalence, 7, 364, 373

stroke incidence, 165, 344

stroke mortality, 164

sudden cardiac death incidence, 68

### SMOKING HABIT

prevalence trends, 336, 344, 346-350, 364-366, 373

Sweden, 111

### SMOKING INTERVENTION TRIALS

cessation outcome, 9, 267-271, 281-283

community-based trials, 271-282, 314-318

individual clinical investigations, 249-271, 303-313, 318, 320

methodological problems, 244-249, 264-267, 280-281, 300-302

### SMOKING PATTERNS

cessation rate effects, 261

CHD incidence, 81-83, 128

CHD mortality rates, 113, 115-119, 127

coronary event risk, 75-76

daily consumption trends, 373

intervention trial effects, 9

low yield cigarettes, 9

myocardial infarction incidence, 87-88

peripheral vascular disease relationship, 185

race factors, 77

reduction of smoking effects, 262

stroke mortality rates, 163-164, 171

sudden cardiac death risk, 7, 104  
trends, 352

### SMOKING PATTERNS—Contd.

women, 101-102, 104

### SNUFF

intermittent claudication relationship, 186

### SOCIOECONOMIC STATUS

CHD mortality rates, 111-112, 339, 350-352

CHD risk factor, 91

coronary atherosclerosis and smoking interrelationships, 33

### STRESS

CHD risk factor, 91

### STROKE

(See also **CEREBROVASCULAR DISEASE**)

atherosclerosis as underlying cause, 16

discharge rate trends, 344

incidence study, 344

mortality trends, 334, 340-341

### SUDDEN CARDIAC DEATH

clinical manifestations, 68-69

risk factors, 104-105

smoking as risk factor in women, 102

smoking pattern relationship, 7, 128

### TARS, TOBACCO

smoking behavior relationship, 371-372

tobacco smoke constituent, 227-228

yields in U.S. cigarettes, 228

### THIOCYANATE

blood levels in smoking baboons, 190

serum levels and lipoproteins, 182

validation of self-reported smoking cessation, 244-246, 258, 261-265, 279-280, 305, 312

### TOBACCO SMOKE

atherosclerosis pathogenesis, 48, 50-56

constituents, 8-9

physical and chemical characteristics, 206-209

### TRIGLYCERIDES

atherosclerosis and plasma concentration, 181

CHD development and plasma levels, 84

CHD incidence, 92

## INDEX

### TRIGLYCERIDES—Contd.

- elevation in peripheral vascular disease, 180
- nicotine effects, 219
- stroke risk factor, 161, 165

### VITAMIN D

- arterial lesions in monkeys caused by dietary excess, 50-51

### WEIGHT GAIN

- cessation of smoking correlation, 96-97, 301

### WOMEN

(See also **MENOPAUSE; ORAL CONTRACEPTIVES; SEX FACTORS**)

- brain infarction and LDL cholesterol, 162
- cardiovascular disease mortality trends, 331
- CHD incidence, mortality, and smoking interrelationships, 101-104, 127-128
- subarachnoid hemorrhage risk and smoking, 5, 167, 170

### ZINC

- tobacco smoke constituent, 227